According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.

Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.

CompletedstrategicpivotfromR&Dfocustocommercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...